How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing (Full text)

and protein expression, in a tissue- and transporter-dependent manner. Depo-Provera-synchronized mice were dosed vaginally or intraperitoneally with (3)H-TFV, with or without MK571 co-administration, to delineate the function of cervicovaginal Mrp4. Co-administration of MK571 significantly increased the concentration of vaginally-administered TFV in endocervix and vagina. MK571 increased the concentration of intraperitoneally-administered TFV in the cervicovaginal lavage and vagina by several fold

2016 Biochemical pharmacology PubMed abstract

202. Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary

) Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent) Barrier methods (e.g., condoms with spermicide) Intrauterine device (i.e., IUD) Vasectomy of male partner Non-heterosexual life style Current evidence or recent history of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data; including but not limited to cardiovascular

2016 Clinical Trials

203. ZIKA Vaccine in Naive Subjects

ring, and depot medroxyprogesterone acetate injection (Depo-Provera), OR Male sex partners must have had a vasectomy >/=3 months prior to first vaccination, OR Practice abstinence defined as refraining from heterosexual intercourse from 30 days before first vaccination until at least 60 days after 2nd vaccination 10. Female subjects must agree to not donate eggs (ova, oocytes) from the start of screening period until at least 60 days after receiving the last vaccination 11. Subjects must provide

2016 Clinical Trials

204. Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies

procedures Female patients of childbearing potential must have a negative pregnancy test within 24 hours of dosing Women of childbearing potential and men who are able to father a child must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for 12 months following administration of the study drug Patients with Multiple Myeloma At least 2 prior regimens

2016 Clinical Trials

205. Restylane Silk Acne Scar Efficacy Evaluation Study

of age. Willing to refrain from undergoing any procedures to repair or augment any acne scar in the treatment area during the study. Female subjects with a negative pregnancy test confirmed at screening and on an acceptable form of birth control. Acceptable forms of birth control on this study include oral or injectable contraceptive, contraceptive patches, Depo-Provera, NuvaRing, Implanon, double barrier methods, IUD, same sex partner, or abstinence. Males will be required to use an acceptable

2016 Clinical Trials

206. The Monitoring Study

, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Need to go outside of the designated geographic boundaries during the study Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days), use of marijuana within 1 month of enrollment, or other substance abuse (use within the last 6 months of controlled

2016 Clinical Trials

207. Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

at the time of screening visit. Complement C4 and C1 inhibitor panel within normal reference ranges. If a woman is of child-bearing potential, she must agree to a reliable form of birth control including: abstinence, oral contraceptives (birth control pills), Depo-provera, an IUD (intrauterine device), or double-barrier contraception (partner using condom and subject using diaphragm). Exclusion Criteria: Unable to give informed written consent, unable to adhere to the outlined visit schedule or unable

2016 Clinical Trials

208. Study of CD133KDEL Toxin in the Treatment for Solid Tumors

or prior known impairment is present. Females of childbearing potential and males who have partners of childbearing potential must agree to use 2 effective contraception methods, one of which must be a barrier method, during the study and for ≥12 weeks after the last dose of dCD133KDEL. Effective methods include intrauterine device (IUD), Depo-Provera injection or implant, Evra patch, NuvaRing, oral contraception, and diaphragm/spermicide with condom. Ability to understand and provide voluntary written

2016 Clinical Trials

209. E4/DRSP Single and Multiple Dose PK and Early QT Study

Previous participation in the current study Use of: combined contraceptives (i.e., COC, Nuvaring®) within 28 days prior to the first dose administration until study completion progestogen-only contraceptive methods (e.g., minipill, implant, or hormonal intrauterine system) within 28 days prior to the first dose administration until study completion depot progestogen preparations or an injectable hormonal method of contraception (e.g., Depo-Provera®) within 6 months prior to the first dose until study

2016 Clinical Trials

210. Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

, it must be have been used for at least 30 days prior to screening, with no planned change in method during the study. The following forms of contraception (per self-report) are permitted: same-sex relationship, male or female sterilization, oral contraceptives, contraceptive implant, contraceptive patch, IUS, IUD depo-medroxyprogesterone acetate (DMPA; Depo-Provera®). 8) Willing to abstain from sexual intercourse/activity including receptive vaginal, oral, digital, and anal intercourse, and the use

2016 Clinical Trials

211. Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

de-novo). For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods

2016 Clinical Trials

212. Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial

and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends. Able to communicate fluently in English. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent/HIPAA form. Exclusion Criteria: Subjects who present with and/or self-report the following

2016 Clinical Trials

213. A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

female partners will use 2 acceptable forms of contraception, one of which must be a condom, until 30 days after the last dose of study drug. Other acceptable forms of contraception include hormonal contraceptives that have been at stable dose for 12 weeks prior to randomization, intrauterine device, Depo-Provera®, Norplant® System Implants, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive sponge, foam, or jelly. Also, male subjects must not donate sperm during

2016 Clinical Trials

214. IV Tranexamic Acid Prior to Hysterectomy

, menorrhagia, uterine fibroids, adenomyosis, pelvic pain, dysmenorrhea, pelvic organ prolapse or endometriosis. Age ≥ 18 years Pre-operative hemoglobin >8 g/dl Willing to have IV tranexamic acid or a placebo prior to hysterectomy Ability to understand and the willingness to sign a written informed consent. Can be previously treated with Depo-Lupron, Depo-Provera, Oral Contraceptive pills, Mirena IUD, endometrial ablation, myomectomy, oral progestins Hysterectomy in combination with the following procedures

2016 Clinical Trials

215. Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

treatment. Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Exclusion Criteria: Non-epithelial ovarian cancers, including

2016 Clinical Trials

216. Vitamin D Supplementation in Women With DCIS and/or LCIS

-string) Exclusion Criteria: Patient desires not to participate in the study Inability to give consent Current use of hormone-containing forms of birth control such as implants (i.e. Norplants, or injectables (i.e. depo-provera) Currently lactating Patients with history of renal or hepatic insufficiency Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication History of granulomatous disease such as tuberculosis or sarcoidosis

2016 Clinical Trials

217. Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstru

to the Screening Visit) Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent) Barrier methods (e.g., condoms with spermicide) Intrauterine device (i.e., IUD) Vasectomy of male partner Non-heterosexual life style Willing and able to provide written informed consent Exclusion Criteria: Current evidence or recent history of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the patients at risk or which

2016 Clinical Trials

218. A Study to Evaluate OPTI-BIOMEâ„¢ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population

control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives (stable for 1 month) including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s

2016 Clinical Trials

219. A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

with demonstrable ischemia Addition or change in dosing of hormonal contraception medications (OCP, IUD, Depo-Provera) in the past 4 weeks. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study or would prevent completion of the study

2016 Clinical Trials

220. Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

of investigational product. Woman who is of childbearing potential (ie, neither surgically sterile nor postmenopausal) and does not agree to use adequate contraception (eg, true abstinence, sterilization, birth control pills, Depo-Provera® [medroxyprogesterone] injections, or contraceptive implants) while on study and for 6 months after the last dose of investigational product. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>